![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, April 1998, p. 974-977, Vol. 42, No. 4
Division of Biomedical Sciences, University
of California, Riverside, California 92521
Received 6 October 1997/Returned for modification 19 December
1997/Accepted 6 February 1998
We demonstrated that a 2% suspension of Pseudomonas
aeruginosa alginate completely blocked the diffusion of
gentamicin and tobramycin, but not that of carbenicillin, illustrating
how alginate production can help protect P. aeruginosa
growing within alginate microcolonies in patients with cystic fibrosis
(CF) from the effects of aminoglycosides. This aminoglycoside diffusion
barrier was degraded with a semipurified preparation of P. aeruginosa alginate lyase, suggesting that this enzyme deserves
consideration as an adjunctive agent for CF patients colonized by
mucoid strains of P. aeruginosa.
Pseudomonas aeruginosa is
one of the most important opportunistic human pathogens (7).
This bacterium is ubiquitous and exhibits innate resistance to a wide
range of antimicrobial agents, making infections both common and
difficult to treat. Patients with cystic fibrosis (CF) have a
multisystem disease due to a biochemical defect in the regulation of
epithelial chloride transport (35) which leads to the
accumulation of thick mucus in the lungs, causing respiratory
congestion and increased susceptibility to bronchopulmonary disease
(14, 42). Despite an aggressive host immune response
(40), patients with CF usually have chronic pulmonary
infections with P. aeruginosa which remain intractable to
antibiotic treatment (17, 30, 38), making P. aeruginosa the predominant cause of death in CF patients
(41). There is also an increasing awareness of the important
role of P. aeruginosa biofilms in the contamination of
medical biomaterials, such as catheters and prostheses (6).
The persistence of P. aeruginosa in CF patient lungs and the
establishment of bacterial biofilms, as well as the bacterial
resistance to antibiotic action and host-mediated clearance mechanisms
in these microniches, has been attributed to the production of an
exopolysaccharide called alginate (6, 17, 22, 29).
Role of alginate.
Alginate produced by mucoid strains of
P. aeruginosa is a polyuronic acid exopolysaccharide
composed of a linear polymer of
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Alginate Lyase Promotes Diffusion of
Aminoglycosides through the Extracellular Polysaccharide of Mucoid
Pseudomonas aeruginosa
ABSTRACT
Top
Abstract
Text
References
TEXT
Top
Abstract
Text
References
1-4 linked D-mannuronic
and L-guluronic acids with O-acetyl side groups
found on C-2 and C-3 of the mannuronic acid residues (the percentage of
acetylation varies from strain to strain) (13). Alginate
production has been shown to inhibit nonopsonic phagocytosis by
monocytes and neutrophils both in vitro (3, 11) and in vivo
(2). Alginate also increases bacterial adherence to the respiratory epithelia (8, 31), thereby increasing the rate of colonization within the respiratory tract.
Sandwich cup assay. We decided to directly examine the ability of P. aeruginosa alginate to prevent the diffusion of various antibiotics, using an adaptation of the sandwich cup assay (20). Alginate was isolated from culture supernatants of P. aeruginosa mucoid strains FRD1 and 144M, both originally obtained from the sputum of patients with CF (27, 33) by the protocol described by Franklin and Ohman (12). A log phase culture of P. aeruginosa FRD2 (a spontaneous nonmucoid derivative of FRD1 [28]) grown in nutrient broth (Becton Dickinson & Co., Cockeysville, Md.) at 37°C, adjusted to an optical density at 600 nm of 0.6, was used as the indicator strain. After a culture plate insert with a 0.4-µm-pore-size filter (12 mm in diameter; Millipore Corporation, Bedford, Mass.) was centered in a 100-mm-diameter petri dish, 15 ml of Antibiotic Medium 11 (Difco Laboratories, Detroit, Mich.) at 47°C was mixed with 50 µl of the bacterial suspension and poured into the dish. After the agar had hardened, 200 µl of either heat-solubilized 1% Noble agar (Difco) or purified 144M or FRD1 alginate preparation (at various concentrations) was placed into the insert and allowed to solidify. Finally, 50 µl of various concentrations of either gentamicin, tobramycin, polymyxin B, or carbenicillin (all from Sigma Chemical Co., St. Louis, Mo.) diluted in one-fourth strength Dulbecco's phosphate-buffered saline (Sigma), pH 8.0, or 50 µl of an antibiotic-alginate lyase mixture was added to the insert. Plates were then incubated overnight at 37°C.
Preliminary experiments determined the optimal levels of antibiotics for use in this sandwich cup assay. Zone sizes representing inhibition of bacterial growth were measured, and the radius (after the contribution of the insert was subtracted) of the zone that was found with Noble agar was defined as representing 100% penetration of antibiotics. The growth inhibition zone size for each antibiotic against strain FRD2 increased linearly as a function of antibiotic concentration (data not shown). Based on these results, we selected antibiotic concentrations which gave consistent growth inhibition radius zone sizes of ~5.50 mm for all subsequent experiments: tobramycin (100 µg), gentamicin (200 µg), carbenicillin (200 µg), and polymyxin B (800 µg).Effect of alginate on antibiotic penetration.
We next examined
whether alginate can affect the growth inhibitory activity of these
antibiotics for strain FRD2. Varying amounts of purified alginate were
substituted for Noble agar in the insert cup, and antibiotics were
placed on top of the alginate prior to incubation. The antibiotic zone
sizes were measured for each alginate concentration and compared to
those obtained with 1% Noble agar as a control. Inhibition of
antibiotic activity for each alginate concentration was determined as
follows: percentage of inhibition = 100 × [1 
(radius with alginate/radius with Noble agar)], and the results are
shown in Fig. 1. When used at
concentrations below 2%, the alginate prepared from strain 144M
demonstrated greater inhibitory activity for tobramycin and for
gentamicin than the alginate from FRD1. (We also noted that at lower
concentrations, 144M alginate is more viscous than FRD1 alginate.)
However, when used at concentrations of 
2%, both alginates
completely blocked the inhibitory activity of both aminoglycosides.
Similar results were obtained with 2% alginate and polymyxin B (data
not shown). In contrast, neither 2% alginate from strain FRD1 nor 2%
alginate from strain 144M blocked the penetration of carbenicillin
(data not shown).
|
Alginate lyase.
Alginates can be enzymatically depolymerized
by lyases (eliminases) which catalyze the cleavage of the glycosidic
linkages by -elimination (32). Alginate lyases are
produced by a wide variety of bacteria, including Bacillus
circulans (19), Klebsiella pneumoniae
(5), various Pseudomonas spp. (36,
39), and P. aeruginosa (4, 9, 21, 24, 34).
In previous studies, we have demonstrated that the alginate lyase
produced by mucoid strains of P. aeruginosa can degrade
alginate (10, 34). To determine whether alginate lyase can
influence antibiotic diffusion through alginate, we first obtained a
semipurified alginate lyase preparation. We constructed pSM13 by
inserting PCR-amplified algL (which encodes the P. aeruginosa FRD1 alginate lyase [34]) into the
expression vector pET21c (Novagen, Inc., Madison, Wis.).
Escherichia coli BL21(DE3)(pSM13) was then grown in Luria
broth-Lennox (Difco) with 100 µg of ampicillin per ml at 25°C
overnight, induced with 1 mM
isopropyl--D-thiogalactopyranoside (IPTG), and incubated for an additional 6 h at 25°C before being harvested. AlgL was extracted from the bacterial pellets by the heat shock procedure described previously (34). After concentration by
ultrafiltration, NaCl was added at a final concentration of 500 mM and
the preparation was fractionated on a Sephacryl HR300 column (Pharmacia
Biotech, Upsala, Sweden) equilibrated with 25 mM
K2HPO4-500 mM NaCl (pH 7.0) at 4°C. Column
fractions were examined for alginate lyase activity by the
thiobarbituric acid assay (34). Enzyme-containing fractions
were pooled and dialyzed overnight with 25 mM
K2HPO4 (pH 7.0) at 4°C, loaded onto a
Sepharose HP ion-exchange column (Pharmacia Biotech), and eluted with a
continuous NaCl gradient from 0 to 500 mM in 25 mM
K2HPO4 (pH 7.0) at 4°C. Enzymatically active
fractions were pooled, concentrated by ultrafiltration, dialyzed
against 25 mM K2HPO4 (pH 7.0) at 4°C, and
stored at 20°C. Enzyme activity was expressed in enzyme units (EU),
where one EU represents the amount of enzyme that produces 1 nmol of
-formyl-pyruvate per min per ml at 37°C (10). Samples
were examined by electrophoresis with a 0.75-mm-thick Laemmli 14%
sodium dodecyl sulfate-polyacrylamide gel which was silver stained
(Fig. 2).
|
Effect of alginate lyase on aminoglycoside diffusion through alginate. Varying amounts of this alginate lyase preparation were mixed with the indicated aminoglycoside (in a final volume of 50 µl) and layered on top of either 2% FRD1 alginate or 2% 144M alginate in the insert cup. The ability of this enzyme to influence aminoglycoside penetration through the alginate preparations was determined by measuring the growth inhibitory zones produced by the aminoglycosides in the presence or absence of the enzyme. The results obtained with FRD1 alginate are shown in Fig. 3. Increasing amounts of alginate lyase decreased the inhibitory activity of 2% FRD1 alginate for both aminoglycosides. When 10.32 EU of alginate lyase was used, the activity of gentamicin for FRD1 was ~79% of that seen in the absence of alginate, whereas that of tobramycin was ~92%. Although a greater number of alginate lyase EU was required to affect aminoglycoside penetration through 144M alginate, 100 AlgL EU restored ~56% of the growth inhibitory activity of gentamicin for strain FRD2 and ~84% of the growth inhibitory activity of tobramycin (Fig. 4). These results demonstrate that this enzyme can degrade both alginate preparations and allows these aminoglycosides to penetrate to the P. aeruginosa FRD2 target organisms.
|
|
Discussion. Our results demonstrate that when used at a final concentration of 2%, alginates prepared from two clinical P. aeruginosa isolates can completely block the ability of gentamicin (at 200 µg), tobramycin (at 100 µg), and polymyxin B (at 800 µg) to inhibit the growth of P. aeruginosa. In contrast, carbenicillin was not inhibited by this concentration of alginate. These results can be interpreted as indicating that the polyanionic alginate acts as an ionic trapping agent for the positively charged aminoglycosides and polymyxin B, a model proposed previously by other investigators (1, 15, 25) and supported by our data.
Gordon et al. (16) found that slime dispersants (such as EDTA or NaCl) can reduce alginate viscosity and facilitate diffusion of the antipseudomonal antibiotics through alginate. In the present study, we demonstrated that alginate lyase, an enzyme purified from P. aeruginosa FRD1, can facilitate diffusion of aminoglycosides to the target bacteria. Although the 144M alginate was somewhat more resistant to the effects of this enzyme than the FRD1 alginate (possibly due to variation in mannuronic-to-guluronic acid ratios or differences in the percentage of acetylation), both alginate preparations were effectively degraded by this enzyme. This result suggests that the blocking activity of the alginate may be due to its ability to form viscous gels as well as to its ionic charge and that when the alginate is degraded, this aminoglycoside-blocking activity is effectively reduced. We and other investigators have suggested that alginate lyase treatment of alginate-encoated bacteria can render them more sensitive to antibiotics or host defenses (2, 11, 23). The present study addresses this issue with a simple, direct assay, the results of which support the hypothesis that degradation of alginate within the lungs of CF patients may render the infecting pathogens more susceptible to aminoglycoside chemotherapy.| |
ACKNOWLEDGMENTS |
|---|
This work was supported in part by grant AI36325 from the National Institutes of Health.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Division of Biomedical Sciences, University of California, Riverside, CA 92521. Phone: (909) 787-4569. Fax: (909) 787-5504. E-mail: neal.schiller{at}ucr.edu.
| |
REFERENCES |
|---|
|
Top
Abstract
Text
References
|
|---|
| 1. | Allison, D. G., and M. J. Matthews. 1992. Effect of polysaccharide interactions on antibiotic susceptibility of Pseudomonas aeruginosa. J. Appl. Bacteriol. 73:484-488[Medline]. |
| 2. |
Bayer, A. S.,
S. Park,
M. C. Ramos,
C. C. Nast,
F. Eftekhar, and N. L. Schiller.
1992.
Effects of alginase on the natural history and antibiotic therapy of experimental endocarditis caused by mucoid Pseudomonas aeruginosa.
Infect. Immun.
60:3979-3985 |
| 3. |
Bayer, A. S.,
D. P. Speert,
S. Park,
J. Tu,
M. Witt,
C. C. Nast, and D. C. Norman.
1991.
Functional role of mucoid exopolysaccharide (alginate) in antibiotic-induced and polymorphonuclear leukocyte-mediated killing of Pseudomonas aeruginosa.
Infect. Immun.
59:302-308 |
| 4. | Boyd, A., M. Ghosh, T. B. May, D. Shinabarger, R. Keogh, and A. M. Chakrabarty. 1993. Sequence of the algL gene of Pseudomonas aeruginosa and purification of its alginate lyase product. Gene 131:1-8[Medline]. |
| 5. | Caswell, R. C., P. Gacesa, K. E. Lutrell, and A. J. Weightman. 1989. Molecular cloning and heterologous expression of a Klebsiella pneumoniae gene encoding alginate lyase. Gene 75:127-134[Medline]. |
| 6. | Costerton, J. W., K.-J. Cheng, G. G. Geesey, T. J. Ladd, J. C. Nickel, M. Dasgupta, and T. J. Marrie. 1987. Bacterial biofilms in nature and disease. Annu. Rev. Microbiol. 41:435-464[Medline]. |
| 7. | Cross, A., J. R. Allen, J. Burke, G. Ducel, A. Harris, J. John, D. Johnson, M. Lew, B. MacMillan, R. Skalova, R. Wenzel, and J. Tenney. 1983. Nosocomial infections due to Pseudomonas aeruginosa: review of recent trends. Rev. Infect. Dis. 5(Suppl.):S837-S845. |
| 8. |
Doig, P.,
N. R. Smith,
T. Todd, and R. T. Irvin.
1987.
Characterization of the binding of Pseudomonas aeruginosa alginate to epithelial cells.
Infect. Immun.
55:864-873 |
| 9. |
Dunne, W. M., Jr., and F. L. A. Buckmire.
1985.
Partial purification and characterization of a polymannuronic acid depolymerase produced by a mucoid strain of Pseudomonas aeruginosa isolated from a patient with cystic fibrosis.
Appl. Environ. Microbiol.
50:562-567 |
| 10. | Eftekhar, F., and N. L. Schiller. 1994. Partial purification and characterization of a mannuronan-specific alginate lyase from Pseudomonas aeruginosa. Curr. Microbiol. 29:37-42. |
| 11. |
Eftekhar, F., and D. P. Speert.
1988.
Alginase treatment of mucoid Pseudomonas aeruginosa enhances phagocytosis by human monocyte-derived macrophages.
Infect. Immun.
56:2788-2793 |
| 12. |
Franklin, M. J., and D. E. Ohman.
1993.
Identification of algF in the alginate biosynthetic gene cluster of Pseudomonas aeruginosa which is required for alginate acetylation.
J. Bacteriol.
175:5057-5065 |
| 13. | Gacesa, P., and N. J. Russell. 1990. The structure and properties of alginate, p. 29-49. In P. Gacesa, and N. J. Russell (ed.), Pseudomonas infection and alginates: biochemistry, genetics and pathology. Chapman and Hall, London, England. |
| 14. | George, R. H. 1987. Pseudomonas infection in cystic fibrosis. Arch. Dis. Child. 62:438-439[Medline]. |
| 15. | Gilbert, P., and M. R. W. Brown. 1995. Mechanisms of the protection of bacterial biofilms from antimicrobial agents, p. 118-130. In H. M. Lappin-Scott, and J. W. Costerton (ed.), Microbial biofilms. Cambridge University Press, Cambridge, Great Britain. |
| 16. |
Gordon, C. A.,
N. A. Hodges, and C. Marriott.
1991.
Use of slime dispersants to promote antibiotic penetration through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
35:1258-1260 |
| 17. |
Govan, J. R. W., and V. Deretic.
1996.
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.
Microbiol. Rev.
60:539-574 |
| 18. |
Govan, J. R. W., and J. A. M. Fyfe.
1978.
Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the mucoid form to carbenicillin, flucloxacillin, and tobramycin and the isolation of mucoid variants in vitro.
J. Antimicrob. Chemother.
4:233-240 |
| 19. |
Hansen, J. B.,
R. S. Doubet, and J. Ram.
1984.
Alginase enzyme production by Bacillus circulans.
Appl. Environ. Microbiol.
47:704-709 |
| 20. | Kumon, H., K. Tomachika, T. Matunaga, M. Ogawa, and H. Ohmori. 1994. A sandwich cup method for the penetration assay of antimicrobial agents through Pseudomonas exopolysaccharides. Microbiol. Immunol. 38:615-619[Medline]. |
| 21. | Linker, A., and L. R. Evans. 1984. Isolation and characterization of an alginase from mucoid strains of Pseudomonas aeruginosa. J. Bacteriol. 159:58-64. |
| 22. |
May, T. B.,
D. Shinabarger,
R. Maharaj,
J. Kato,
L. Chu,
J. D. DeVault,
S. Roychoudhury,
N. A. Zielinsky,
A. Berry,
R. K. Rothmel,
T. K. Misra, and A. M. Chakrabarty.
1991.
Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients.
Clin. Microbiol. Rev.
4:191-196 |
| 23. | Meluleni, G. J., M. Grout, D. J. Evans, and G. B. Pier. 1995. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. J. Immunol. 155:2029-2038[Abstract]. |
| 24. | Nguyen, L. K., and N. L. Schiller. 1989. Identification of a slime exopolysaccharide depolymerase in mucoid strains of Pseudomonas aeruginosa. Curr. Microbiol. 18:323-329. |
| 25. |
Nichols, W. W.,
S. M. Dorrington,
M. P. E. Slack, and H. L. Walmsley.
1988.
Inhibition of tobramycin diffusion by binding to alginate.
Antimicrob. Agents Chemother.
32:518-523 |
| 26. | Nichols, W. W., M. J. Evans, M. P. E. Slack, and H. L. Walmsley. 1989. The penetration of antibiotics into aggregates of mucoid and non-mucoid Pseudomonas aeruginosa. J. Gen. Microbiol. 135:1291-1303[Medline]. |
| 27. |
Ohman, D. E., and A. M. Chakrabarty.
1981.
Genetic mapping of chromosomal determinants for the production of the exopolysaccharide alginate in a Pseudomonas aeruginosa cystic fibrosis isolate.
Infect. Immun.
33:142-148 |
| 28. |
Ohman, D. E., and A. M. Chakrabarty.
1982.
Utilization of human respiratory secretions by mucoid Pseudomonas aeruginosa of cystic fibrosis origin.
Infect. Immun.
37:662-669 |
| 29. | Pedersen, S. S. 1992. Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis. APMIS 100(Suppl. 28):1-79. |
| 30. | Pier, G. B. 1985. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction. J. Infect. Dis. 151:575-580[Medline]. |
| 31. |
Ramphal, R.,
C. Guay, and G. B. Pier.
1987.
Pseudomonas aeruginosa adhesins for tracheobronchial mucin.
Infect. Immun.
55:600-603 |
| 32. | Romeo, T., and J. F. Preston, III. 1986. Depolymerization of alginate by an extracellular alginate lyase from a marine bacterium: substrate specificity and accumulation of reaction products. Biochemistry 25:8391-8396. |
| 33. | Schiller, N. L., and R. A. Hatch. 1983. The serum sensitivity, colonial morphology, serogroup specificity, and outer membrane protein of Pseudomonas aeruginosa strains isolated from several clinical sites. Diagn. Microbiol. Infect. Dis. 1:143-157. |
| 34. |
Schiller, N. L.,
S. R. Monday,
C. M. Boyd,
N. T. Keen, and D. E. Ohman.
1993.
Characterization of the Pseudomonas aeruginosa alginate lyase gene (algL): cloning, sequencing and expression in Escherichia coli.
J. Bacteriol.
175:4780-4789 |
| 35. | Sferra, T. J., and F. S. Collins. 1993. The molecular biology of cystic fibrosis. Annu. Rev. Med. 44:133-144[Medline]. |
| 36. | Sutherland, I. W., and G. A. Keen. 1981. Alginases from Beneckea pelagia and Pseudomonas species. J. Appl. Biochem. 3:48-57. |
| 37. | Thomassen, M. J., C. A. Demko, B. Boxerbaum, R. C. Stern, and P. J. Kuchenbrod. 1979. Multiple isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J. Infect. Dis. 140:873-880[Medline]. |
| 38. | Thomassen, M. J., C. A. Demko, and C. F. Doershuk. 1987. Cystic fibrosis: a review of pulmonary infections and interventions. Pediatr. Pulmonol. 3:334-351[Medline]. |
| 39. |
Von Riesen, L. V.
1980.
Digestion of algin by Pseudomonas maltophilia and Pseudomonas putida.
Appl. Environ. Microbiol.
39:92-96 |
| 40. |
Warner, J. O.
1992.
Immunology of cystic fibrosis.
Br. Med. Bull.
48:893-911 |
| 41. | Welsh, M. J., L.-C. Tsui, T. F. Boat, and A. L. Beaudet. 1995. Cystic fibrosis, p. 3799-3876. In C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle (ed.), The metabolic basis of inherited disease. McGraw-Hill, Inc., New York, N.Y. |
| 42. | Wood, R. E., T. F. Boat, and C. F. Doershuk. 1976. Cystic fibrosis: state of the art. Am. Rev. Respir. Dis. 113:833-878[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |
